Pfiz­er buys in­to de­cen­tral­ized co­op­er­a­tive to ac­cel­er­ate R&D in hu­man longevi­ty

The biggest of Big Phar­ma is turn­ing over a new, edgi­er leaf, propos­ing to spend $500,000 to join a new co­op­er­a­tive, known as Vi­taDAO, for com­mu­ni­ty-gov­erned and de­cen­tral­ized drug de­vel­op­ment fo­cused on ex­tend­ing hu­man life.

The co­op­er­a­tive aims to bet­ter align var­i­ous forms of ear­ly-stage fund­ing in longevi­ty bio­phar­ma through a com­bo of nov­el and buzz­word-heavy frame­works like de­cen­tral­ized au­tonomous or­ga­ni­za­tions, non-fun­gi­ble to­kens, and fi­nan­cial en­gi­neer­ing tools that run on the Ethereum blockchain.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.